EXoZymes Common Stock Net 2024-2025 | EXOZ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

EXoZymes common stock net from 2024 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

EXoZymes common stock net from 2024 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$213.1B
Amgen (AMGN)	$159.1B
Gilead Sciences (GILD)	$134.7B
Vertex Pharmaceuticals (VRTX)	$117.7B
Bristol Myers Squibb (BMY)	$95B
CSL (CSLLY)	$81.2B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$58.9B
Alnylam Pharmaceuticals (ALNY)	$41.8B
Argenex SE (ARGX)	$34.6B
BioNTech SE (BNTX)	$26.2B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13B
Exelixis (EXEL)	$12.1B
Moderna (MRNA)	$12B
BioMarin Pharmaceutical (BMRN)	$10.8B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.3B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.8B